U.S. markets closed

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0200+0.0200 (+2.00%)
At close: 04:00PM EST
1.0000 -0.02 (-1.96%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close1.0000
Bid1.0000 x 1400
Ask1.0300 x 1400
Day's Range0.9900 - 1.0300
52 Week Range0.8900 - 2.3300
Avg. Volume186,545
Market Cap10.241M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-2.1600
Earnings DateFeb 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ONVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organovo Holdings, Inc.
    DDD: What does Argus have to say about DDD?3D SYSTEMS CORP has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • Simply Wall St.

    Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

    Organovo Holdings ( NASDAQ:ONVO ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.60m (loss widened by...

  • Zacks Small Cap Research

    ONVO Continues Progress

    By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 3Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.40 per share, inline with estimates as expenses remained

  • GlobeNewswire

    Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

    SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the